about
The role of epigenetic mechanisms and processes in autoimmune disordersA new era in the treatment of multiple sclerosisTherapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association oGender differences in autoimmune disease.Gene expression in the spinal cord in female lewis rats with experimental autoimmune encephalomyelitis induced with myelin basic proteinExposing asymmetric gray matter vulnerability in amyotrophic lateral sclerosis.Neurofilaments as Biomarkers for Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis.Recombinant EPF/chaperonin 10 promotes the survival of O4-positive pro-oligodendrocytes prepared from neonatal rat brain.Sexual dimorphism in autoimmune disease.Effects of gender in amyotrophic lateral sclerosis.Guillain-barré syndrome: modern theories of etiology.Role of gender in multiple sclerosis: clinical effects and potential molecular mechanisms.Body mass index and dietary intervention: implications for prognosis of amyotrophic lateral sclerosis.Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of NeuroloTherapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association ofMultiparity in women with multiple sclerosis causes less long-term disability: no.A combined tract-based spatial statistics and voxel-based morphometry study of the first MRI scan after diagnosis of amyotrophic lateral sclerosis with subgroup analysis.Defining secondary progressive multiple sclerosis.Altered Metabolic Homeostasis in Amyotrophic Lateral Sclerosis: Mechanisms of Energy Imbalance and Contribution to Disease Progression.Assessment of Motor Units in Neuromuscular Disease.Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.Extra-motor abnormalities in amyotrophic lateral sclerosis: another layer of heterogeneity.Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.Genetics of Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): current knowledge and future directions.Predictors of long-term disability accrual in relapse-onset multiple sclerosis.A simple and reliable immunohistochemical method for colocalization of 2 antigens in the same cells of paraffin-embedded tissues.A protective effect of early pregnancy factor on experimental autoimmune encephalomyelitis induced in Lewis rats by inoculation with myelin basic protein.The frequencies of Killer immunoglobulin-like receptors and their HLA ligands in chronic inflammatory demyelinating polyradiculoneuropathy are similar to those in Guillian Barre syndrome but differ from those of controls, suggesting a role for NK ceContribution of different relapse phenotypes to disability in multiple sclerosis.Clinical features and impact of myasthenia gravis disease in Australian patients.Targeted assessment of lower motor neuron burden is associated with survival in amyotrophic lateral sclerosis.Serial measurements of phosphorylated neurofilament-heavy in the serum of subjects with amyotrophic lateral sclerosis.Killer immunoglobulin-like receptor and their HLA ligands in Guillain-Barré Syndrome.Biomarkers of disease in a case of familial lower motor neuron ALS.Use of respiratory function tests to predict survival in amyotrophic lateral sclerosis.A developmental perspective on bulbar involvement in amyotrophic lateral sclerosis.Clinical features of patients with Guillain-Barré syndrome at seven hospitals on the East Coast of Australia.Growth hormone secretion is correlated with neuromuscular innervation rather than motor neuron number in early-symptomatic male amyotrophic lateral sclerosis mice.Use of Bayesian MUNE to show differing rate of loss of motor units in subgroups of ALS.Correlation of adrenomedullin gene expression in peripheral blood leukocytes with severity of ischemic stroke.
P50
Q28389137-4F1F021C-45C0-477E-B89C-075B15BE83ADQ29395420-FE725F75-8011-4394-A744-6742B749224AQ30834551-28B6CEBB-03AF-42E9-9165-DE30B24FD5DFQ34040802-EE06D96F-99DE-4901-B157-B9FFDEE8416EQ34472020-7446A5BA-A3C2-4F73-981E-0E9C5676F836Q35221959-4303F840-E8A4-4FC2-883F-297124D71F16Q36161527-A5E2A7D8-FCCE-4035-9928-E6C2A3EEE836Q37171000-DECCEB0E-56D5-46FE-A5EF-7EF5A7705584Q37595548-CC3A18C2-87AC-4914-88AD-D8EA1918AF56Q37825010-D7C8EDC8-06A3-4225-9ABC-9C15E614AE3FQ37859643-A4820229-C658-46A4-82BF-0D5DABE89087Q37862835-63FB5478-D294-4B31-8E63-CAEFEE377FA3Q38195974-AC3F1483-CE2A-441D-B2C1-9C8737E1A2C6Q38226014-7A023E33-6559-4403-A565-569EC218BA6FQ38226016-B669D235-B963-46AA-8995-ACD761DF4287Q38262637-D6E027C6-AF06-4BFF-A4C4-EC3C6D43CA19Q38627441-C7EFA94B-DB23-4F26-AE95-B8A7E54B3E66Q38843046-CE8B7AF7-3338-4327-A8C3-8E8F3156FB86Q38892519-DF85DFE4-396A-40E6-B23D-BC8A79A51096Q38947718-84EBC865-459E-4DEB-89A3-77FF66945B66Q38956663-23333998-D8F8-416F-8BEF-0D032A9CE5A6Q39041271-96E8A4C1-862A-4B9D-AE51-5A58BE8D03AEQ39139645-0D696FCB-13A3-447E-BB0C-80DD39009B28Q39157513-4FA1A16F-566A-4719-B5B2-ACCEB0605644Q39795220-75A5DDC2-8E22-491C-A9AA-F2023597C8C8Q40077688-35FD7413-EB0D-4246-9378-C24BB0E5BAFEQ40618520-BEB636A8-2538-4A7A-A54F-9F71CE4DA911Q40710502-52DEDB7A-BE36-4AAA-8FF5-717947504B1AQ40724148-6F3DC4F0-3D37-4E10-90EA-E766627344AAQ40892716-5BCB5610-B3F6-480E-A249-6D28CDC155A7Q41024423-D2205440-E4E6-4EB8-8116-03A4D02B53EDQ41750088-938A95AE-449B-498D-8C05-19C6D07E8C0BQ42235573-1A29A454-12CA-437B-9E83-6BE1849CF485Q43080320-3F61F1AC-D1E0-404A-BB67-DDD673FE1491Q43492209-6CB6A088-2383-4ACE-A79A-705230EE2AACQ44208864-43ABB76A-C338-4EB4-A784-2136EFA33EEEQ44466268-B8E14B9F-19D6-4086-911B-2EF00921F28FQ44761953-1951EB90-DBDC-4B8B-876F-57CFEC67E557Q44958485-038492E1-D233-452D-8B4B-B83848828C7FQ46056898-7815A741-DC95-4DB1-877D-6F5A217297CB
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Pamela A McCombe
@nl
Pamela A McCombe
@sl
Pamela A. McCombe
@en
Pamela A. McCombe
@es
type
label
Pamela A McCombe
@nl
Pamela A McCombe
@sl
Pamela A. McCombe
@en
Pamela A. McCombe
@es
prefLabel
Pamela A McCombe
@nl
Pamela A McCombe
@sl
Pamela A. McCombe
@en
Pamela A. McCombe
@es
P1053
C-9692-2010
P106
P1153
7006403442
P21
P31
P3829
P496
0000-0003-2704-8517